Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Michael W KonstanWayne J Morgan

Abstract

Previously we assessed risk factors for FEV(1) decline in children and adolescents using the Epidemiologic Study of Cystic Fibrosis (J Pediatr 2007;151:134-139); the current study assessed risk factors in adults. Risk factors for FEV(1) decline over 3-5.5 years for ages 18-24 and ≥25 years were assessed using mixed-model regression. Mean rates of FEV(1) decline (% predicted/year) were -1.92 for ages 18-24y (n=2793) and -1.45 for ages ≥25y (n=1368). For the 18-24y group, B. cepacia, pancreatic enzyme use, multidrug-resistant P. aeruginosa, cough, mucoid P. aeruginosa, and female sex predicted greater decline; low baseline FEV(1) and sinusitis predicted less decline. For the ≥25y group, only pancreatic enzyme use predicted greater decline; low baseline FEV(1) and sinusitis predicted less decline. Risk factors for FEV(1) decline in adults <25 years are similar to those previously identified in children and adolescents; older adults had few statistically significant risk factors.

References

Feb 1, 1991·Archives of Disease in Childhood·J S Forsyth
Aug 1, 1995·Journal of Clinical Epidemiology·C A DemkoP B Davis
Oct 28, 1993·The New England Journal of Medicine·UNKNOWN Cystic Fibrosis Genotype-Phenotype Consortium
Jan 15, 1998·The Journal of Pediatrics·M CoreyM Knowles
Jan 5, 1999·American Journal of Respiratory and Critical Care Medicine·J L HankinsonK B Fedan
May 10, 2002·Pediatric Pulmonology·C SchaedelL Holmberg
Jul 12, 2002·Statistics in Medicine·Mark D SchluchterPamela B Davis
Jul 24, 2007·The Journal of Pediatrics·Michael W KonstanUNKNOWN Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
Nov 23, 2007·The New England Journal of Medicine·Theodore G LiouBarbara C Cahill
Jul 22, 2010·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·M W KonstanD R VanDevanter
Mar 26, 2011·Pediatric Pulmonology·Michael W KonstanUNKNOWN Scientific Advisory Group and Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis

❮ Previous
Next ❯

Citations

Dec 18, 2013·Paediatric Respiratory Reviews·K HerscovitchLarry C Lands
Jun 21, 2014·Revista clínica española·M LerínR Alvarez-Sala
Sep 22, 2015·The Journal of Pediatrics·Wayne J MorganUNKNOWN Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis
Sep 11, 2013·Pediatric Pulmonology·Carlos E MillaUNKNOWN KB001 Study Group
Oct 26, 2013·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Audrey TluczekPhilip M Farrell
Jul 2, 2015·American Journal of Respiratory and Critical Care Medicine·Gregory S SawickiMichael W Konstan
Mar 11, 2015·Pediatric Pulmonology·Michael W KonstanCharles Johnson
Dec 23, 2014·Pediatric Pulmonology·Michael S SchechterMichael W Konstan
Sep 16, 2014·Respirology : Official Journal of the Asian Pacific Society of Respirology·Alex Horsley, Salman Siddiqui
Jun 19, 2015·Pediatric Pulmonology·Margaret RosenfeldUNKNOWN Investigators of Coordinators of the Epidemiologic Study of Cystic Fibrosis
Jun 5, 2016·Paediatric Respiratory Reviews·Sabariah Noor HarunStefanie Hennig
Oct 18, 2016·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·K De Boeck, A Zolin
Jan 21, 2016·Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia·João Paulo Heinzmann-FilhoMárcio Vinícius Fagundes Donadio
Mar 23, 2017·Annals of the American Thoracic Society·Wayne J MorganUNKNOWN Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis
Nov 4, 2017·The New England Journal of Medicine·Jennifer L Taylor-CousarJ Stuart Elborn
Jun 2, 2018·Expert Review of Respiratory Medicine·Natalie E West, Patrick A Flume
May 26, 2018·Orphanet Journal of Rare Diseases·Dominique Pougheon BertrandGilles Rault
May 19, 2018·The European Respiratory Journal·Marieke van HorckEdward Dompeling
Jun 29, 2017·ERJ Open Research·Mirai MizutaniSimon Rousseau
Jun 5, 2019·International Forum of Allergy & Rhinology·Anna C ZemkeStella E Lee
May 23, 2014·Medicine and Science in Sports and Exercise·Erik H J HulzebosTim Takken
Dec 10, 2019·Statistics in Medicine·Rhonda D SzczesniakJohn P Clancy
Nov 3, 2015·Current Opinion in Infectious Diseases·Katherine M LanganAnton Y Peleg
Sep 19, 2019·Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquée, Nutrition Et Métabolisme·María Del M Martínez-GarcíaJuan D Ruiz-Cárdenas
Feb 26, 2020·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Daniel J LeeJohn M Lee
Feb 26, 2015·Journal of Pediatric Gastroenterology and Nutrition·Evans MachoguPraveen S Goday
Nov 8, 2019·The New England Journal of Medicine·Peter G MiddletonUNKNOWN VX17-445-102 Study Group
Aug 18, 2017·Pediatric Pulmonology·Emily E BarskyGregory S Sawicki
May 24, 2018·BMC Pulmonary Medicine·Jürgen SchäferDominik Hartl
Feb 26, 2019·Therapeutic Advances in Respiratory Disease·Jaime L RubinTheodore G Liou
Dec 2, 2020·Journal of Clinical Medicine·Marta Garcia-ClementeMiguel Angel Martinez-García
Jan 13, 2021·Pediatric Pulmonology·Michael W KonstanUNKNOWN Scientific Advisory Group and the Investigators and Coordinators of ESCF
May 10, 2020·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·L CaleyD G Peckham

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.